Association between Plasma Adipocytokines Levels and Intracranial versus Extracranial Atherosclerotic among Chinese Patients with Stroke
Background: To detect the levels of plasma Adipocytokines, TNF-α, IL-6 and PAI-1 in patients with intracranial and extracranial arteriosclerosis.
Methods: From September 2015 to September 2017, 318 patients aged ≥60 years were enrolled. Overall, 192 patients were included in the case group (intracranial and extracranial arteriosclerosis group). The 196 outpatients who matched the case groupware selected as the control group. The levels of plasma APN, TNF-α, IL-6 and PAI-1 were measured and their inter- and intra-group comparisons were performed using t-test or analysis of variance. Multivariate logistic regression analysis was used to study the correlation between intracranial arteriosclerosis and extracranial arteriosclerosis.
Results: The level of plasma APN in the intracranial and extracranial arteriosclerosis group was significantly lower than that in the control group (P=0.025). The plasma levels of PAI-1, TNF-α and IL-6 were obviously higher than those in the control group (P=0.003, P=0.008, P=0.043). In the intracranial arteriosclerosis group, the level of plasma APN in patients with arterial stenosis ≥70% was significantly lower than that in patients with stenosis 30%-69% (P=0.028).
Conclusion: Plasma APN, PAI-1, IL-6 and TNF-α levels can be used as monitoring indicators of intracranial and extracranial arteriosclerosis. Intracranial arteriosclerosis is significantly associated with the decrease of plasma APN level and the increase of plasma PAI- 1, IL-6 and TNF-α levels.
2. Lam RC, Lin SC, DeRubertis B, Hynecek R, Kent KC, Faries PL (2007). The impact of increasing ageonanatomic factors af-fecting carotid angioplasty and stenting. J Vasc Surg, 45(5): 875-880.
3. Sitzer M, Skutta M, Siebler M, Sitzer G, Siegrist J, Steinmetz H (1998). Modifiable stroke risk factors in volunteers willing to participate in a prevention program. Neu-roepidemiology, 17 (4):179-187.
4. Leung SY, Ng TH, Yuen ST, Lauder IJ, Ho FC (1993). Pattern of cerebral atheros cle-rosis in Hong Kong Chinese. Severity in intracranial and extracranial vessels. Stroke, 24 (6):779-886.
5. Kasner SE, Chimowitz MI, Lynn MJ et al (2006). Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation, 113(4):555-63.
6. Higashida RT, Meyers PM, Connors JJ et al (2009). Intracranial angioplasty and stent-ing for cerebral atherosclerosis: aposition statement of the American Society of In-terventional and Therapeutic Neuroradi-ology, Society of Interventional Radiolo-gy, and the American Society of Neuro-radiology. J Vasc Interv Radiol, 20 (7 Suppl): S312-316.
7. Kalita J, Misra UK, Kumar B, Somarajan BI, Kumar S, Mittal B (2013). ACE and ADD1 gene in extra and intracranial ath-erosclerosis in ischaemic stroke. Neurol Res, 35 (4): 429-434.
8. Kim BJ, Lee KM, Lee SH et al (2018). Eth-nic Differences in Intracranial Artery Tor-tuosity: A Possible Reason for Different Locations of Cerebral Atherosclerosis. J Stroke, 20 (1): 140-141.
9. Vaccarezza M, Balla C, Rizzo P (2018). Ath-erosclerosis as an inflammatory disease: Doubts? No more. Int J Cardiol Heart Vasc, 19: 1-2.
10. Bang OY, Lee PH, Yoon SR, Lee MA, Joo IS, Huh K (2005). Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA ath-erosclerosis. J Neurol Neurosurg Psychiatry, 76 (8): 1128-34.
11. HJM B, Taylor DW, Haynes RB et al (1991). Beneficial effect of carotid endarterecto-my in symptomatic patients with high-grade carotid stenosis. N Engl J Med, 325(7): 445-453.
12. Alberti KG, Zimmet P, Shaw J et al (2005). The metabolic syndrome--a new world-wide definition. Lancet, 366 (9491):1059-1062.
13. Koleva DI, Orbetzova MM, Nikolova JG, Deneva TI (2016). Pathophysiological Role of Adiponectin, Leptin and Asym-metric Dimethylarginine in the Process of Atherosclerosis. Folia Med (Plovdiv), 58 (4):234-240.
14. Yoon JH, Kim SK, Choi HJ et al (2013). Adiponectin provides additional infor-mation to conventional cardiovascular risk factors for assessing the risk of ath-erosclerosis in both genders. PLoS One, 8 (10):e75535.
15. Hasan-Ali H, Abd ENA, Hamed HB, Abd-Elsayed A (2011). Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron Artery Dis, 22 (4): 264-269.
16. Persson J, Folkersen L, Ekstrand J et al (2012). High plasma adiponectin concen-tration is associated with all-cause mor-tality in patients with carotid atherosclero-sis. Atherosclerosis, 225 (2):491-496.
17. Prugger C, Luc G, Haas B et al (2012). Adi-pocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol, 71 (4):478-486.
18. Saarikoski LA, Huupponen RK, Viikari JS et al (2010). Adiponectin is related with ca-rotid artery intima-media thickness and brachial flow-mediated dilatation in young adults-- the Cardiovascular Risk in Young Finns Study. Ann Med, 42 (8):603-611.
19. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B (2005). Plasma adiponectin levels and so-nographic phenotypes of subclinical ca-rotid artery atherosclerosis: data from the SAPHIR Study. Stroke, 36 (12):2577-2582.
20. Shargorodsky M, Boaz M, Goldberg Y et al (2009). Adiponectin and vascular proper-ties in obese patients: is it a novel bi-omarker of early atherosclerosis. Int J Obes (Lond), 33 (5): 553-558.
21. Bang OY, Saver JL, Ovbiagele B, Choi YJ, Yoon SR, Lee KH (2007). Adiponectin levels in patients with intracranial athero-sclerosis. Neurology, 68 (22):1931-1937.
22. Kim BJ, Lee SH, Ryu WS, Kim CK, Yoon BW (2012). Adipocytokines and ischemic stroke: differential associations between stroke subtypes. J Neurol Sci, 312 (1-2): 117- 122.
23. Gorgui J, Gasbarrino K, Georgakis MK et al (2017). Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mor-tality: A systematic review and meta-analyses. Metabolism, 69: 51-66.
24. Nishida M, Moriyama T, Ishii K et al (2007). Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical ather-osclerosis. Clin Chim Acta, 384 (1-2):99-104.
25. Sakata T, Mannami T, Baba S et al (2004). Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Ather-osclerosis, 176 (2):355-360.
26. Reda E, Hassaneen S, El-Abhar HS (2018). Novel Trajectories of Bromocriptine An-tidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1. Front Pharmacol, 9: 771.
27. Chen L, He T, Han Y, Sheng JZ, Jin S, Jin MW (2011). Pentamethylquercetin im-proves adiponectin expression in differ-entiated 3T3-L1 cells via a mechanism that implicates PPARγ together with TNF-α and IL-6. Molecules, 6(7): 5754-68.
28. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003). Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol, 14 (6): 561-566.
|Issue||Vol 49 No 4 (2020)|
|Adipocytokines Intracranial arteriosclerosis; Extracranial arteriosclerosis; Risk factors|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|